Caffeic acid phenethyl amide improves glucose homeostasis and attenuates the progression of vascular dysfunction in Streptozotocin-induced diabetic rats

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Ho, Yi Jin ^a   Chen, Wen Pin ^a   Chi, Tzong Cherng ^b   Chang Chien, Ching Chia ^a   Lee, An Sheng ^c   Chiu, Hsi Lin ^d   Kuo, Yueh Hsiung ^d   Su, Ming Jai ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Caffeic acid phenethyl amide; Diabetes; Vascular dysfunction

Indexed keywords

ANTIDIABETIC AGENT; CAFFEIC ACID DERIVATIVE; CAFFEIC ACID PHENETHYL AMIDE; GLUCOSE; INSULIN; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; PHENETHYL ALCOHOL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART MUSCLE CONTRACTILITY; MALE; NONHUMAN; RAT; THORACIC AORTA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; CASE CONTROL STUDY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; SECRETION (PROCESS); SYNTHESIS; WISTAR RAT;

ANIMALS; AORTA; BLOOD GLUCOSE; CAFFEIC ACIDS; CASE-CONTROL STUDIES; CORONARY CIRCULATION; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PHENYLETHYL ALCOHOL; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 84879812091     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-99     Document Type: Article

References (53)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35(Suppl 1):S64-71. 3632174, 22187472, American Diabetes Association.
2. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes 2008, 26:77-82.
3. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005, 109:143-159.
4. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005, 90:5896-5903. 10.1210/jc.2005-0754, 16014401.
5. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the american diabetes association and the american heart association. Circulation 2006, 113:2943-2946. 10.1161/CIRCULATIONAHA.106.176583, 16801475.
6. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46:760-765. 10.1007/s00125-003-1116-6, 12774166.
7. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2007, 30:2107-2112. 10.2337/dc06-1441, 2654598, 17468351.
8. Kumar S, Singh R, Vasudeva N, Sharma S. Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol 2012, 11:9. 10.1186/1475-2840-11-9, 3286385, 22257465.
9. Rydgren T, Vaarala O, Sandler S. Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J Pharmacol Exp Ther 2007, 323:180-185. 10.1124/jpet.107.122655, 17636011.
10. Weng YC, Chuang ST, Lin YC, Chuang CF, Chi TC, Chiu HL, Kuo YH, Su MJ. Caffeic acid phenylethyl amide protects against the metabolic consequences in diabetes mellitus induced by diet and streptozocin. Evid Based Complement Alternat Med 2012, 2012:984780. 3388606, 22778782.
11. Mar GYKP, Chen LJ, Cheng KC, Li YX, Cheng JT. Increase in cardiac M2-muscarinic receptor expression is regulated by GATA binding protein 4 (GATA-4) in streptozotocin-induced diabetic rats. Int J Cardiol 2013, 167:436-441. 10.1016/j.ijcard.2012.01.015, 22293779.
12. Aloysius UI, Achike FI, Mustafa MR. Mechanisms underlining gender differences in phenylephrine contraction of normoglycaemic and short-term streptozotocin-induced diabetic WKY rat aorta. Vascul Pharmacol 2012, 57:81-90. 10.1016/j.vph.2011.11.009, 22172524.
13. Felaco M, Grilli A, De Lutiis MA, Patruno A, Libertini N, Taccardi AA, Di Napoli P, Di Giulio C, Barbacane R, Conti P. Endothelial nitric oxide synthase (eNOS) expression and localization in healthy and diabetic rat hearts. Ann Clin Lab Sci 2001, 31:179-186.
14. Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol 2011, 10:105. 10.1186/1475-2840-10-105, 3248842, 22107602.
15. Chang KS, Stevens WC. Endothelium-dependent increase in vascular sensitivity to phenylephrine in long-term streptozotocin diabetic rat aorta. Br J Pharmacol 1992, 107:983-990. 10.1111/j.1476-5381.1992.tb13395.x, 1907920, 1467844.
16. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care 2009, 32(Suppl 2):S253-259. 2811456, 19875560.
17. Toyoda T, Tsukamoto T, Takasu S, Shi L, Hirano N, Ban H, Kumagai T, Tatematsu M. Anti-inflammatory effects of caffeic acid phenethyl ester (CAPE), a nuclear factor-kappaB inhibitor, on helicobacter pylori-induced gastritis in mongolian gerbils. Int J Cancer 2009, 125:1786-1795. 10.1002/ijc.24586, 19610061.
18. Fesen MR, Pommier Y, Leteurtre F, Hiroguchi S, Yung J, Kohn KW. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 1994, 48:595-608. 10.1016/0006-2952(94)90291-7, 7520698.
19. Lee KW, Kang NJ, Kim JH, Lee KM, Lee DE, Hur HJ, Lee HJ. Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa B. Genes Nutr 2008, 2:319-322. 10.1007/s12263-007-0067-9, 2478489, 18850224.
20. Velazquez C, Navarro M, Acosta A, Angulo A, Dominguez Z, Robles R, Robles-Zepeda R, Lugo E, Goycoolea FM, Velazquez EF, Astiazaran H, Hernandez J. Antibacterial and free-radical scavenging activities of sonoran propolis. J Appl Microbiol 2007, 103:1747-1756. 10.1111/j.1365-2672.2007.03409.x, 17953585.
21. Okutan H, Ozcelik N, Yilmaz HR, Uz E. Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. Clin Biochem 2005, 38:191-196. 10.1016/j.clinbiochem.2004.10.003, 15642285.
22. Cicala C, Morello S, Iorio C, Capasso R, Borrelli F, Mascolo N. Vascular effects of caffeic acid phenethyl ester (CAPE) on isolated rat thoracic aorta. Life Sci 2003, 73:73-80. 10.1016/S0024-3205(03)00235-2, 12726888.
23. Hishikawa K, Nakaki T, Fujita T. Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25:442-446.
24. Tamer L, Sucu N, Ercan B, Unlu A, Calikoglu M, Bilgin R, Degirmenci U, Atik U. The effects of the caffeic acid phenethyl ester (CAPE) on erythrocyte membrane damage after hind limb ischaemia-reperfusion. Cell Biochem Funct 2004, 22:287-290. 10.1002/cbf.1102, 15338467.
25. Celik S, Erdogan S, Tuzcu M. Caffeic acid phenethyl ester (CAPE) exhibits significant potential as an antidiabetic and liver-protective agent in streptozotocin-induced diabetic rats. Pharmacol Res 2009, 60:270-276. 10.1016/j.phrs.2009.03.017, 19717012.
26. Hsu FL, Chen YC, Cheng JT. Caffeic acid as active principle from the fruit of xanthiumstrumarium to lower plasma glucose in diabetic rats. Planta Med 2000, 66:228-230. 10.1055/s-2000-8561, 10821047.
27. Fuliang HU, Hepburn HR, Xuan H, Chen M, Daya S, Radloff SE. Effects of propolis on blood glucose, blood lipid and free radicals in rats with diabetes mellitus. Pharmacol Res 2005, 51:147-152. 10.1016/j.phrs.2004.06.011, 15629260.
28. Matsui T, Ebuchi S, Fujise T, Abesundara KJ, Doi S, Yamada H, Matsumoto K. Strong antihyperglycemic effects of water-soluble fraction of brazilian propolis and its bioactive constituent, 3,4,5-tri-O-caffeoylquinic acid. Biol Pharm Bull 2004, 27:1797-1803. 10.1248/bpb.27.1797, 15516726.
29. Tolan I, Ragoobirsingh D, Morrison EY. Isolation and purification of the hypoglycaemic principle present in capsicum frutescens. Phytother Res 2004, 18:95-96. 10.1002/ptr.1328, 14750210.
30. Mahesh T, Sri Balasubashini MM, Menon VP. Photo-irradiated curcumin supplementation in streptozotocin-induced diabetic rats: effect on lipid peroxidation. Therapie 2004, 59:639-644. 10.2515/therapie:2004110, 15789828.
31. Yang J, Kerwin SM, Bowman PD, Stavchansky S. Stability of caffeic acid phenethyl amide (CAPA) in rat plasma. Biomed Chromatogr 2012, 26:594-598. 10.1002/bmc.1702, 21915890.
32. Yang J, Marriner GA, Wang X, Bowman PD, Kerwin SM, Stavchansky S. Synthesis of a series of caffeic acid phenethyl amide (CAPA) fluorinated derivatives: comparison of cytoprotective effects to caffeic acid phenethyl ester (CAPE). Bioorg Med Chem 2010, 18:5032-5038. 10.1016/j.bmc.2010.05.080, 20598894.
33. Nishioka TW, Kawabata J, Niki J, Niki R. Isolation and activity of N-p-coumaroyltyramine, an α-glucosidase inhibitor in welsh onion (allium fistulosum). Biosci Biotechnol Biochem 1997, 61:4.
34. Yamazaki Y, Kawano Y, Uebayasi M. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid. Life Sci 2008, 82:290-300. 10.1016/j.lfs.2007.11.016, 18166202.
35. Weng YC, Chiu HL, Lin YC, Chi TC, Kuo YH, Su MJ. Antihyperglycemic effect of a caffeamide derivative, KS370G, in normal and diabetic mice. J Agric Food Chem 2010, 58:10033-10038. 10.1021/jf1024246, 20804127.
36. Weng YC, Chuang CF, Chuang ST, Chiu HL, Kuo YH, Su MJ. KS370G, A synthetic caffeamide derivative, improves left ventricular hypertrophy and function in pressure-overload mice heart. Eur J Pharmacol 2012, 684:108-115. 10.1016/j.ejphar.2012.03.029, 22484506.
37. Chi TC, Ho YJ, Chen WP, Chi TL, Lee SS, Cheng JT, Su MJ. Serotonin enhances beta-endorphin secretion to lower plasma glucose in streptozotocin-induced diabetic rats. Life Sci 2007, 80:1832-1838. 10.1016/j.lfs.2007.02.016, 17397876.
38. Ku PM, Chen LJ, Liang JR, Cheng KC, Li YX, Cheng JT. Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractility. Cardiovasc Diabetol 2011, 10:57. 10.1186/1475-2840-10-57, 3141394, 21702924.
39. Katovich MJ, Meldrum MJ, Vasselli JR. Beneficial effects of dietary acarbose in the streptozotocin-induced diabetic rat. Metabolism 1991, 40:1275-1282. 10.1016/0026-0495(91)90028-U, 1961120.
40. Johansen O, Vaaler S, Jorde R, Reikeras O. Increased plasma glucose levels after hypnorm anaesthesia, but not after pentobarbital anaesthesia in rats. Lab Anim 1994, 28:244-248. 10.1258/002367794780681723, 7967463.
41. Chi TC, Chen WP, Chi TL, Kuo TF, Lee SS, Cheng JT, Su MJ. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci 2007, 80:1713-1720. 10.1016/j.lfs.2007.02.002, 17346750.
42. Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, Irminger JC, Kergoat M, Portha B, Homo-Delarche F, Donath MY. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 2009, 106:13998-14003. 10.1073/pnas.0810087106, 2729009, 19666548.
43. Chi TC, Lee SS, Su MJ. Antihyperglycemic effect of aporphines and their derivatives in normal and diabetic rats. Planta Med 2006, 72:1175-1180. 10.1055/s-2006-947199, 16924583.
44. Bernier M, Curtis MJ, Hearse DJ. Ischemia-induced and reperfusion-induced arrhythmias: importance of heart rate. Am J Physiol 1989, 256:H21-31.
45. Lee AS, Chen WP, Su MJ. Comparison of the cardiac electrophysiological effects between doxazosin and bunazosin. J Biomed Sci 2008, 15:519-528. 10.1007/s11373-008-9249-8, 18427952.
46. Chiao CW, da Silva-Santos JE, Giachini FR, Tostes RC, Su MJ, Webb RC. P2X7 Receptor activation contributes to an initial upstream mechanism of lipopolysaccharide-induced vascular dysfunction. Clin Sci (Lond) 2013, 125:131-141.
47. Ulker S, Cinar MG, Bayraktutan U, Evinc A. Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells. Cardiovasc Res 2001, 50:589-596. 10.1016/S0008-6363(01)00268-1, 11376635.
48. Yu X, Tesiram YA, Towner RA, Abbott A, Patterson E, Huang S, Garrett MW, Chandrasekaran S, Matsuzaki S, Szweda LI, Gordon BE, Kem DC. Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovasc Diabetol 2007, 6:6. 10.1186/1475-2840-6-6, 1805425, 17309798.
49. Wei M, Ong L, Smith MT, Ross FB, Schmid K, Hoey AJ, Burstow D, Brown L. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ 2003, 12:44-50. 10.1046/j.1444-2892.2003.00160.x, 16352106.
50. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002, 51(Suppl 3):S368-376.
51. Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006, 8:385-396. 10.1089/dia.2006.8.385, 16800760.
52. Ferlito S, Puleo F, Carra G, Damante G, Di Vincenzo S, Del Campo F. Effect of alpha-1-blockade by prazosin on blood sugar, insulin and glucagon levels in normals and non-insulin dependent diabetics. J Endocrinol Invest 1983, 6:199-202.
53. Cavallo-Perin P, Bruno A, Cassader M, Cesco L, Gruden G, Pagano G. The glucoregulatory and antilipolytic actions of insulin in abdominal obesity with normal or impaired glucose tolerance: an in vivo and in vitro study. Eur J Clin Invest 1992, 22:725-731. 10.1111/j.1365-2362.1992.tb01436.x, 1478241.